2026年大年初十，央视网全媒体推出大型文化系列节目《问茶中国》。首篇以热辣滚烫的方式，开 启山城重庆的千年茶韵。 《问茶中国·重庆篇》从茶树到茶火锅，从制茶到吃茶，全方位呈现茶产业的完整链条。 一千两百余年前，茶圣陆羽著就传世佳作《茶经》。而今，《问茶中国》接过这脉茶香，踏遍青 山，寻访散落于中国大地的茶之瑰宝。这不仅是一次味觉的溯源，更是一场为当代健康饮品修典的壮 举。 当问茶之旅抵达山城重庆，寻茶的视角在烟火中泡开。泡，是方法，更是态度。重庆的茶，就泡在 这座城市的沸腾与闲适中。 以茶为媒：打造文旅新IP，激活乡村新动能 在"绿水青山就是金山银山"理念指引下，茶产业正成为融合生态保护、文化传承与乡村振兴的重要 载体。 《问茶中国·重庆篇》从一棵茶树鼻祖出发。这棵位于南川金佛山的古茶树，历经雷击而不死，见 证着人与茶共生的历史。它不仅守护着这片绿水青山，更守护着山城茶香的根。 节目深度挖掘金佛山独有的"三奇"现象：颠覆常识的"寒芽孕翠"，古茶树在冬季积蓄能量，静待春 发；地质奇观"雷音伴祖"，泉眼因地质构造发出如雷轰鸣，千年不绝；以及以油熬茶、当饭吃的"干劲 汤"，一碗下肚，爬坡有劲。 这三奇不仅是金佛山 ...

2010年，黄崇硕毕业于台湾中兴大学农业经营管理专业。两年后，带着对大陆市场的憧憬，他前往天津 一家台资企业从事无土栽培技术研发、市场策划等工作。2014年，他奔赴上海，将目光聚焦农业品牌运 营管理，一步步积累经验。 "初来乍到，就被大陆蓬勃的发展活力吸引。"黄崇硕表示，他一直很关注大陆在农业农村领域的相关政 策，"尤其在2018年，乡村振兴战略深入实施，我相信其中大有可为。" 2020年，黄崇硕入职嘉兴桐乡市现代农业创新服务中心。当时，他对当地6个镇、3个街道的240多种农 特产品进行全面摸排，并通过中央厨房集中展示，现场教授游客烹饪技巧。 "我在台湾考取了园艺技术师、面包烘焙技术师、景观造园技术师等证照，平时也比较喜欢研究美 食。"黄崇硕介绍，他为桐乡一家蘑菇厂量身打造了13道蘑菇料理，深受游客好评，"我还把台湾成熟的 休闲农业运营模式免费推介给当地农场，为农户增收出一份力"。 中新社浙江台州2月17日电 题：台胞别样"登陆日记"：多重跨界遇见更好的自己 作者 傅飞扬 "从农田里的蔬果到车间里的仪器，从精密制造到医疗器械，一转眼我来大陆14年了，每次跨界都像一 场'重生'。"正值春节假期，回首在大陆深耕的 ...

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue up to 94,936,708 A-shares to its controlling shareholder, Changjiang Industrial Investment Group, raising a total of no more than 600 million yuan, which will improve the company's financial status and enhance its resilience against macroeconomic fluctuations [1][3] Group 1: Fundraising and Shareholding Structure - The fundraising will be used to repay loans and supplement working capital, which is expected to improve the company's financial condition [3][5] - After the issuance, Changjiang Industrial Group's shareholding will significantly increase, demonstrating the controlling shareholder's confidence in the company's long-term development [1][3] Group 2: Strategic Positioning and Industry Context - Changjiang Industrial Group is the only provincial-level industrial investment platform in Hubei, focusing on strategic emerging industries, including biomedicine [3][4] - The company aligns with Hubei's "14th Five-Year Plan," which emphasizes the development of high-end medical devices and biomedicine as key growth areas [4] Group 3: Business Structure and Competitive Advantages - Guangji Pharmaceutical is a major global supplier of Vitamin B2, with a market share of approximately 30%, and has a strong operational efficiency and cost control [5][7] - The company has a long history of technological accumulation in Vitamin B2 production, maintaining stable customer relationships and a robust supply chain [7][9] Group 4: Market Trends and Future Outlook - The Vitamin B2 market is entering a down cycle but is expected to recover as global feed demand increases and synthetic biology technology reshapes cost structures [9] - The 600 million yuan fundraising is seen as the beginning of a transformation from a traditional manufacturer to a health platform enterprise [9]

Core Viewpoint - Shengyuan Environmental (300867) reported stable operations in its main business areas of waste incineration power generation and urban sewage treatment, with continuous optimization in operational quality and profitability, indicating a solid and improving fundamental outlook [1] Group 1: Business Operations - The company’s main business segments, waste incineration power generation and urban sewage treatment, are performing steadily [1] - Operational quality and profitability are continuously improving, reflecting a strong fundamental performance [1] Group 2: New Business Initiatives - The company is actively expanding into the health industry, focusing on taurine raw materials and their derivatives [1] - The taurine raw material project is set to commence production soon, which is expected to cultivate new growth drivers and long-term development momentum for the company [1] - Stakeholders are encouraged to pay attention to the relevant sections in the company's 2025 annual report for further insights [1]

Core Viewpoint - The appointment of Zhou Jianzhong as the new CEO of Kewang Pharmaceutical reflects the company's commitment to professionalizing its management team and modernizing its governance system, ensuring stability in its core management structure and continuity in strategic development [1][2]. Governance System Optimization - The change in the CEO position does not alter the stability of Kewang Pharmaceutical's core management team, as evidenced by adjustments in the board's specialized committees, which maintain strategic continuity and professionalism [2]. - The strategic committee now includes Chairman Guan Yuxiu, Guan Yi, and new CEO Zhou Jianzhong, while the compensation and assessment committee consists of Miao Jiajun, Zhao Yan, and Guan Yi [2][3]. - Zhou Jianzhong, with a strong background in the pharmaceutical industry, is well-suited for the company's current development stage, having held key management positions in several well-known pharmaceutical companies [3]. Strategic Development - Kewang Pharmaceutical is actively adapting to industry trends and deepening its strategic transformation, focusing on the health industry as a key growth area [4]. - The company aims to leverage its "Xiao Kewang" brand advantage to develop a multi-channel operational system, emphasizing both prescription and OTC pharmaceuticals alongside health products [4]. Brand and Market Position - The combined brand value of "Kewang" for adult health and "Xiao Kewang" for children's health exceeds 36.5 billion, with leading consumer recognition in the industry [5]. - The company has established a marketing network covering 8,000 hospitals and 450,000 retail terminals, forming strategic partnerships with 500 pharmaceutical distribution companies to support its health product expansion [5]. Product Development - Kewang Pharmaceutical holds over 1,000 drug approval numbers, with more than 500 in the medical insurance directory and nearly 300 in the basic drug directory, including around 30 exclusive varieties [6]. - The company plans to enhance research and development in core areas such as elderly care, children's health, and women's health, with several health products already in the approval process [6]. Management Upgrade and Future Outlook - The stable core management team and clear strategic layout provide a solid foundation for Kewang Pharmaceutical, with the professional management team expected to inject new vitality into the company's growth [7]. - The management upgrade reflects the company's strategic determination to adapt to industry changes and optimize its governance structure, positioning it for high-quality development driven by policy benefits and market demand [7].

本报讯（记者 孙颖）位于地铁16号线看丹站西南角的丰台区看丹村绿隔产业项目日前顺利完成封顶。 作为"看丹数字健康智谷"创新产业园区的先行示范区，这组建筑与看丹站D口一体化设计，以办公+商 业的模式，将打造一处"轨道微中心"+"大健康"产业融合式示范街区。 走进工地，五栋大楼合围，钢筋铁骨倍显崔巍。据悉，该项目是看丹数字健康科技文化产业园区的先行 示范区，规划设计亮点十足——地下空间将直接与已通车的地铁16号线看丹站实现无缝接驳，充分体 现"轨道+城市"融合理念。项目将围绕轨道站点，全力打造总规模超9万平方米的TOD城市综合体，将建 设成为京西南地区极具辨识度的城市新地标。 "这五栋建筑总建筑面积9.05万平方米，其中地上建筑面积5.82万平方米，地下建筑面积3.23万平方米， 1号楼、3号楼和4号楼是商业楼，2号楼和5号楼是办公楼。"中铁城建集团第一工程有限公司副总经理谢 彪介绍，从去年5月正式进场以来，仅用9个月就完成了结构封顶，比预计工期提前了2个月。 直接与已通车的地铁16号线看丹站连通，也意味着施工难度大大增加。谢彪介绍，项目基坑距离地铁16 号线隧道结构最近的距离只有2米，守护"地下动脉"平稳运行， ...

【浙商轻工】华宝国际：大额减值影响表观利润，大手笔回购强化信心 公司计划于1.28日起的12个月内展开股份回购，最多5亿港币。 1）华宝国际各项业务均加大出海转型力度，其中烟用胶囊（爆珠）增长迅猛、成为业绩重要拉动，再造烟叶（薄 片）具备3000吨产能、产能利用率有望提升，香精与调味品也不断开发海外市场。 < 【浙商轻工】华宝国际：大额减值影响表观利润，大手笔回购强化信心 华宝国际2025年将录得税前亏损约2.63-3.43亿元，较上年减亏15-35%，主要系以下因素拖累： 1）股权激励带来的薪酬开支0.98亿元。 2）子公司嘉豪食品商誉减值4.7-5.3亿元。 单看香精板块业务，25年实现利润6500-9500万元。 华宝国际2025年将录得税前亏损约2.63-3.43亿元，较上年减亏15-35%，主要系以下因素拖累： 1）股权激励带来的薪酬开支0.98亿元。 2）子公司嘉豪食品商誉减值4.7-5.3亿元。 单看香精板块业务，25年实现利润6500-9500万元。 2）12月通过旗下子公司在济南、江西开始布局大健康产业基地，切入营养保健品、功能性食品等细分赛道，增量 可期。 风险提示：海外新业务推进不及预期 ...

齐鲁晚报·齐鲁壹点 王佳潼 通讯员 赵永德 李春臻 从山间一株平凡草药，到标准化商品，再到承载非遗底蕴的产品，从农民肩挑背扛的零星售卖，到合作 社规模化的订单农业，再到直播间里面向全国的生动推介，寺头镇的中草药产业，完成了一场从"泥 土"到"云端"，从"产品"到文化的华丽蝶变。 晨光熹微，寺头镇淘宝村的直播间里已氤氲起药香。女主播手持一袋色泽红艳的丹参片，声音清 亮："我们寺头的丹参，以丹参酮含量高而闻名全国。它色红如丹，质密油润，入口甘醇......"，镜头前 丹参片、黄芪片、山楂片、红枣片、桑葚干等保健茶饮铺陈开来，宛如色彩斑斓的草本画卷。她一边将 暗红的丹参片、金黄的黄芪片、鲜红的山楂片放在一起，一边娓娓道来："黄芪、山楂跟丹参搭配，就 是著名的三通茶，有通淤、通气、通管道之功效……"主播继续口吐莲花，双手不断地调换药材，或化 浊降脂、或补肾益智，或助眠安神、或补血养颜的茶饮组方不断变换。屏幕另一端天南地北的订单纷至 沓来，寺头的山野精灵正凭借一根网线、一方屏幕构建的商路，化作千家万户茶盏里最熨帖的守护。 这片土地与中草药的缘分，深植于农耕文明的年轮里。曾几何时，药香只在山间寂寞飘散。药农们依着 祖辈的 ...

中新网漳州1月21日电 (廖珍妹)21日，福建漳州市政协十四届五次会议举行，参会的漳州市政协港澳委 员怀揣桑梓深情，围绕家乡高质量发展建言献策。港澳委员一致认为，漳州现代化滨海城市建设蓝图清 晰，与港澳在医药、教育、人才、产业等方面极具合作前景，未来发展可期。 香港漳州同乡总会副会长徐斌深耕药店经营20余年，去年数次赴漳州考察，十分关注家乡大健康产业发 展。他在受访时指出，漳州"圆山计划"推动下的中医药产业发展令人瞩目，尤其五大工程之一的"名医 入漳"项目集聚众多优质医疗资源。在他看来，未来漳州和香港可互聘名医，通过借鉴成功案例推动两 地医师交流，共同开拓大健康市场。 当天会议，港澳委员还围绕漳州产业发展、对外开放、民生改善、文旅和经贸互通、人员互访等方面积 极发言。(完) 图为21 "漳州是'中国食品名城'，香港可成为漳州龙头食品企业'走出去'的重要跳板。"朱淮林表示，漳州企业 可在香港注册公司，搭建跨境平台，依托香港的国际网络与制度优势，更高效地开拓海外市场、开展跨 境投资。 漳州籍港澳乡亲多达10万人，两地互动频繁。澳门漳州同乡总会常务副会长、澳门科技大学招生处助理 行政主任黄玮关注漳州与澳门的教育协同 ...

Core Viewpoint - The company is undergoing a critical period of deep adjustment and transformation in the pharmaceutical industry, emphasizing the importance of each step in its development and focusing on innovation, quality, talent strategy, and diversified layout to drive transformation and upgrade [1] R&D-Driven Strategic Transformation - Northeast Pharmaceutical is a significant drug production and export base in China, focusing on innovation and core business development, achieving important results in R&D breakthroughs and quality improvement [1] - The company has increased R&D investment, accelerating the transition of innovative results from the laboratory to clinical applications [2] - The DCTY0801 injection, developed by its subsidiary Dingcheng Peptide Source, received approval for clinical trials targeting specific types of high-grade brain gliomas, marking a substantial breakthrough in innovative drug development for tumor treatment [1][2] Quality Assurance for Market Expansion - Strong R&D capabilities have provided essential support for product quality enhancement, with quality being described as the lifeline for pharmaceutical companies [2] - The company's core raw material product, phosphomycin aminobutyric acid, received the European Pharmacopoeia suitability certificate (CEP) in 2025, becoming the first domestic company to obtain this certification, enhancing the brand image and competitiveness of Chinese raw materials in the international high-end market [3] - The company passed a surprise inspection by the FDA with a "zero defect" score, demonstrating its leading quality control system across the entire production and management chain [3] Comprehensive Value Enhancement through Layout - While deepening its core business, the company is actively expanding into related fields based on its professional advantages in pharmaceutical R&D and production [4] - The company has developed four health biscuits based on the concept of "food and medicine homology," enriching its existing product matrix in food and health products [4] - The launch of the skincare brand "Qifangyuan" represents the company's entry into the beauty sector, integrating pharmaceutical technology with skincare product development [4] Recognition and Achievements - The company's comprehensive business layout and solid operational results have enhanced its overall strength, leading to recognition from various sectors [5] - In 2025, Northeast Pharmaceutical was included in the list of "National Intellectual Property Demonstration Enterprises" recommended by Liaoning Province and re-certified as a national high-tech enterprise [5] - The company was awarded the title of "Top 100 Pharmaceutical Industrial Enterprises by Revenue for 2024-2025" in industry evaluations [5]